PULSE BIOSCIENCES INC (PLSE) Stock Price, Forecast & Analysis
USA - NASDAQ:PLSE - US74587B1017 - Common Stock
PLSE Key Statistics, Chart & Performance
The current stock price of PLSE is 16.7 USD. In the past month the price decreased by -11.03%. In the past year, price increased by 16.04%.
PLSE Latest News, Press Relases and Analysis
PLSE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.64 | 214.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 61.77 | 190.64B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.05 | 148.86B | ||
| SYK | STRYKER CORP | 27.09 | 136.39B | ||
| MDT | MEDTRONIC PLC | 16.37 | 116.10B | ||
| BDX | BECTON DICKINSON AND CO | 12.5 | 51.13B | ||
| IDXX | IDEXX LABORATORIES INC | 52.65 | 50.59B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.25 | 48.65B | ||
| RMD | RESMED INC | 25 | 36.12B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.12 | 33.78B | ||
| DXCM | DEXCOM INC | 31.66 | 23.09B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.48 | 26.35B |
Related stock screener links
About PLSE
Company Profile
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. The company is headquartered in Hayward, California and currently employs 75 full-time employees. The company went IPO on 2016-05-18. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The company is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
Company Info
PULSE BIOSCIENCES INC
3957 Point Eden Way
Hayward CALIFORNIA 94545 US
CEO: Darrin R. Uecker
Employees: 75
Phone: 15109064600
PULSE BIOSCIENCES INC / PLSE FAQ
What does PLSE do?
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. The company is headquartered in Hayward, California and currently employs 75 full-time employees. The company went IPO on 2016-05-18. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The company is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
What is the stock price of PULSE BIOSCIENCES INC today?
The current stock price of PLSE is 16.7 USD. The price decreased by -1.18% in the last trading session.
What is the dividend status of PULSE BIOSCIENCES INC?
PLSE does not pay a dividend.
How is the ChartMill rating for PULSE BIOSCIENCES INC?
PLSE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does PULSE BIOSCIENCES INC belong to?
PULSE BIOSCIENCES INC (PLSE) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Can you provide the market cap for PULSE BIOSCIENCES INC?
PULSE BIOSCIENCES INC (PLSE) has a market capitalization of 1.12B USD. This makes PLSE a Small Cap stock.
What is the ownership structure of PULSE BIOSCIENCES INC (PLSE)?
You can find the ownership structure of PULSE BIOSCIENCES INC (PLSE) on the Ownership tab.
PLSE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to PLSE. When comparing the yearly performance of all stocks, PLSE is one of the better performing stocks in the market, outperforming 74.19% of all stocks.
PLSE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PLSE. PLSE has a great financial health rating, but its profitability evaluates not so good.
PLSE Financial Highlights
Over the last trailing twelve months PLSE reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS decreased by -33.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.57% | ||
| ROE | -65.11% | ||
| Debt/Equity | 0 |
PLSE Forecast & Estimates
7 analysts have analysed PLSE and the average price target is 22.44 USD. This implies a price increase of 34.37% is expected in the next year compared to the current price of 16.7.